Bristol Myers is in a great position both fundamentally and technically. Time horizon is 1-2 years.
Technical: Ascending Triangle with Price above the 30-day and 210-day simple moving averages. This could squeeze into the previous highs set in 2018 and 2016 (~$75). We want to see the price continue to stay above these averages as well as the trend line connecting the recent higher lows.
Fundamental: -Recent Celgene acquisition adds 18B in revenue and diversifies BMY's product portfolio. Before the acquisition, BMY's Top 3 Drugs made up almost 75% of its total revenue. After the acquisition this same ratio is only 43%, decreasing BMY's reliance on its top 3 drugs. -Last three years the average P/E based on operating earnings for BMY has been 14.21, and at their current price they are trading at a 9.79, suggesting they may be currently undervalued. -Dividend of $1.92 or 3.14% yield -21.41% Adjusted Operating Earnings growth rate -A+ S&P credit rating